Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$2.5B |
| 2 |
Apple
AAPL
|
+$1.68B |
| 3 |
Tesla
TSLA
|
+$951M |
| 4 |
Johnson & Johnson
JNJ
|
+$750M |
| 5 |
UnitedHealth
UNH
|
+$703M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CTXS
Citrix Systems Inc
CTXS
|
+$913M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$257M |
| 3 |
NVIDIA
NVDA
|
+$225M |
| 4 |
Vertiv
VRT
|
+$164M |
| 5 |
JPMorgan Chase
JPM
|
+$161M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 12.48% |
| 2 | Healthcare | 7.36% |
| 3 | Financials | 6.5% |
| 4 | Consumer Discretionary | 5.35% |
| 5 | Industrials | 3.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2526
Replimune Group
REPL
$994M
| $1.31M | ﹤0.01% |
48,144
-1,529
| -3% | -$31.8K |
|
2527
Kulicke & Soffa
KLIC
$4.91B
| $1.31M | ﹤0.01% |
29,531
+1,838
| +7% | +$80.8K |
|
|
PNT
2528
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $1.3M | ﹤0.01% |
178,498
+83,695
| +88% | +$621K |
|
2529
ImmunityBio
IBRX
$7.68B
| $1.3M | ﹤0.01% |
256,365
+3,335
| +1% | +$18.3K |
|
|
MMX
2530
DELISTED
Maverix Metals Inc. Common Shares
MMX
| $1.3M | ﹤0.01% |
277,624
| – | – |
|
2531
Northwest Bancshares
NWBI
$2.34B
| $1.3M | ﹤0.01% |
92,824
+45,807
| +97% | +$660K |
|
2532
Q2 Holdings
QTWO
$3.97B
| $1.3M | ﹤0.01% |
48,287
+13,429
| +39% | +$375K |
|
|
FFWM
2533
DELISTED
First Foundation Inc
FFWM
| $1.3M | ﹤0.01% |
90,457
+8,502
| +10% | +$132K |
|
2534
Ingevity
NGVT
$2.65B
| $1.3M | ﹤0.01% |
18,401
+5,694
| +45% | +$401K |
|
2535
Hain Celestial
HAIN
$50.3M
| $1.29M | ﹤0.01% |
79,875
-20,321
| -20% | -$362K |
|
|
AUY
2536
DELISTED
Yamana Gold, Inc.
AUY
| $1.29M | ﹤0.01% |
232,478
-114,080
| -33% | -$576K |
|
|
FLNA
2537
Filana Therapeutics
FLNA
$46.4M
| $1.29M | ﹤0.01% |
43,656
+22,114
| +103% | +$795K |
|
|
HAIA
2538
DELISTED
Healthcare AI Acquisition Corp. Class A Ordinary Shares
HAIA
| $1.29M | ﹤0.01% |
125,618
| – | – |
|
2539
Franco-Nevada
FNV
$43.7B
| $1.29M | ﹤0.01% |
9,440
-4,195
| -31% | -$554K |
|
2540
Itron
ITRI
$4.62B
| $1.29M | ﹤0.01% |
25,411
+3,534
| +16% | +$175K |
|
2541
W&T Offshore
WTI
$484M
| $1.29M | ﹤0.01% |
230,588
+21,379
| +10% | +$147K |
|
2542
Golar LNG
GLNG
$5.11B
| $1.28M | ﹤0.01% |
56,340
+44,470
| +375% | +$1.11M |
|
2543
Harmony Biosciences
HRMY
$2.23B
| $1.28M | ﹤0.01% |
23,259
-881
| -4% | -$48.4K |
|
2544
AMC Entertainment Holdings
AMC
$2.38B
| $1.28M | ﹤0.01% |
31,478
-19,396
| -38% | -$1.22M |
|
2545
iShares US Transportation ETF
IYT
$2.28B
| $1.28M | ﹤0.01% |
+23,988
| New | +$1.3M |
|
2546
Alector
ALEC
$165M
| $1.28M | ﹤0.01% |
138,741
-17,867
| -11% | -$156K |
|
2547
Assured Guaranty
AGO
$3.66B
| $1.28M | ﹤0.01% |
20,566
-3,755
| -15% | -$223K |
|
2548
J&J Snack Foods
JJSF
$1.59B
| $1.28M | ﹤0.01% |
8,552
+661
| +8% | +$98.1K |
|
2549
AGNC Investment
AGNC
$12.6B
| $1.28M | ﹤0.01% |
123,517
-734,582
| -86% | -$6.71M |
|
2550
Brighthouse Financial
BHF
$3.55B
| $1.28M | ﹤0.01% |
24,903
+782
| +3% | +$40.9K |
|
Similar funds
Barclays's Q4 2022 Portfolio in Review
As of Q4 2022, Barclays held 5,646 positions worth $223B, up 144% from $91.6B the previous quarter. Its ten largest holdings account for 41% of the portfolio.
Barclays deployed $128B of net new capital in Q4 2022, opening 797 new positions and adding to 2,634 existing holdings. Its largest new stake was Seadrill: 1,546,558 shares worth $50.5M.
By sector, the portfolio is most concentrated in Technology at 12% of assets, down from 23% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $257M trimmed.
- Barclays's largest Q4 2022 buy was Seadrill: 1,546,558 shares worth $50.5M.
- Barclays added most to Microsoft in Q4 2022, an estimated $2.5B increase.
- Barclays's biggest Q4 2022 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $257M.
- Barclays fully exited Citrix Systems Inc in Q4 2022, selling an estimated $913M.
- Barclays's ten largest holdings make up 41% of its $223B portfolio in Q4 2022.
- Barclays opened 797 new positions and closed 385 in Q4 2022.
- Barclays's portfolio value rose 144% quarter-over-quarter to $223B.
Based on Barclays's 13F filing for Q4 2022, filed 13 Feb 2023.